Study on Rituximab's Effects in Rheumatoid Arthritis
Author Information
Author(s): Thurlings R M, Vos K, Wijbrandts C A, Zwinderman A H, Gerlag D M, Tak P P
Primary Institution: Academic Medical Centre/University of Amsterdam
Hypothesis
To investigate the synovial tissue in patients with rheumatoid arthritis (RA) treated with rituximab and to identify possible predictors of clinical response.
Conclusion
Rituximab treatment leads to a decrease in synovial plasma cells, which is associated with clinical improvement in rheumatoid arthritis patients.
Supporting Evidence
- The 28-joint Disease Activity Score (DAS28) significantly decreased at 16 and 24 weeks after treatment.
- Serum levels of IgM-rheumatoid factor (RF) decreased significantly at 24 weeks.
- The reduction of plasma cells predicted clinical improvement at 24 weeks.
Takeaway
This study shows that a medicine called rituximab helps people with arthritis by reducing certain cells in their joints that cause inflammation.
Methodology
24 patients with RA underwent synovial biopsy before, 4 and 16 weeks after rituximab treatment, with immunohistochemical analysis and linear regression to identify predictors of clinical response.
Limitations
The study had a small sample size and variability in patient responses.
Participant Demographics
Median age 55 years (range 22–75), 75% female, all patients had erosive disease.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website